Patent intelligence · US
US 11833160
Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseases
Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseases
Patent details — US 11833160
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 5, 2023
- Expiration
- Nov 30, 2043
- Claims
- 8
- CPC classes
- A61K, A61K31/575, A61K31/58, A61P
Quick answer
US 11833160 (Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseases) is held by UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERTSITATEA. Status: granted. Granted Dec 5, 2023. Expires Nov 30, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K31/575, A61K31/58, A61P, A61P1/04, A61P1/16
More from UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERTSITATEA
Related pharmaceutical patents in our USPTO index.
-
US 12226429
Highly active compounds against COVID-19
granted -
US 12084473
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 12006340
Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
granted -
US 12005139
Ophthalmic formulations and related methods
granted -
US 11975016
2′-substituted-N6-substituted purine nucleotides for RNA virus treatment
granted -
US 11964047
Ophthalmic formulations and related methods
granted -
US 11813278
Highly active compounds against COVID-19
granted
Frequently asked questions
What is US patent 11833160?
US 11833160 (Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseases) is held by UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERTSITATEA. Status: granted. Granted Dec 5, 2023. Expires Nov 30, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11833160?
UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERTSITATEA is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 35 pharmaceutical patents for this assignee.
When does US 11833160 expire?
Our index shows an expiration date of Nov 30, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.